Aurinia Pharmaceuticals Inc. achieved a significant financial turnaround in 2025 with net product sales of LUPKYNIS up 25% year-over-year to $271.3 million, fueling its first positive operating and net income since prior losses. The oral lupus nephritis therapy benefits from patent protection through 2037 and collaboration with Otsuka for international commercialization, though ongoing patent litigation poses risk. Strong operating cash flow and aggressive share repurchases spotlight effective capital allocation but depend on maintaining sales growth and regulatory compliance.